Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis
- PMID: 19672926
- DOI: 10.1002/bjs.6731
Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis
Abstract
Background: A combined antiviral and tumoricidal effect of interferon (IFN) is assumed to occur after resection or ablation of hepatocellular carcinoma (HCC).
Methods: An electronic search of the Medline, Embase and Central databases from January 1998 to October 2007 was conducted to identify randomized controlled trials evaluating adjuvant effects of IFN after curative treatment of HCC. A meta-analysis was performed to estimate the effects of IFN on 2-year outcome.
Results: Seven trials enrolling a total of 620 patients were included in the meta-analysis. Adjuvant treatment with IFN significantly reduced the 2-year mortality rate after curative treatment of HCC, with a pooled risk ratio of 0.65 (95 per cent confidence interval 0.52 to 0.80); P < 0.001) in absence of any significant heterogeneity (I(2) = 0 per cent, P = 0.823 for chi(2)). The effect on reduction of tumour recurrence was less pronounced but still significant (pooled risk ratio 0.86 (95 per cent c.i. 0.76 to 0.97); P = 0.013). IFN had to be discontinued in 8-20 per cent of patients.
Conclusion: IFN has a significant beneficial effect after curative treatment of HCC in terms of both survival and tumour recurrence.
(c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Similar articles
-
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x. Aliment Pharmacol Ther. 2010. PMID: 20659285 Review.
-
Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis.Adv Clin Exp Med. 2015 Mar-Apr;24(2):331-40. doi: 10.17219/acem/29760. Adv Clin Exp Med. 2015. PMID: 25931368 Review.
-
Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.Ann Surg. 2012 Jan;255(1):8-17. doi: 10.1097/SLA.0b013e3182363ff9. Ann Surg. 2012. PMID: 22104564 Clinical Trial.
-
Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis.World J Gastroenterol. 2010 Jun 21;16(23):2931-42. doi: 10.3748/wjg.v16.i23.2931. World J Gastroenterol. 2010. PMID: 20556841 Free PMC article.
-
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach.J Hepatol. 2010 Jun;52(6):889-94. doi: 10.1016/j.jhep.2009.12.041. Epub 2010 Mar 24. J Hepatol. 2010. PMID: 20395009
Cited by
-
How I treat hepatitis C virus infection in patients with hematologic malignancies.Blood. 2016 Sep 15;128(11):1449-57. doi: 10.1182/blood-2016-05-718643. Epub 2016 Jul 21. Blood. 2016. PMID: 27443290 Free PMC article.
-
Recent advances in liver resection for hepatocellular carcinoma.Front Surg. 2014 Jun 16;1:21. doi: 10.3389/fsurg.2014.00021. eCollection 2014. Front Surg. 2014. PMID: 25593945 Free PMC article. Review.
-
Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.Hepat Mon. 2011 Aug;11(8):612-9. doi: 10.5812/kowsar.1735143x.721. Hepat Mon. 2011. PMID: 22140384 Free PMC article.
-
Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.Front Med. 2021 Apr;15(2):155-169. doi: 10.1007/s11684-021-0848-3. Epub 2021 Mar 23. Front Med. 2021. PMID: 33754281 Review.
-
Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.BMC Cancer. 2010 Nov 10;10:620. doi: 10.1186/1471-2407-10-620. BMC Cancer. 2010. PMID: 21062497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical